UK Launches Human Trials for Rapidly Developed Ebola Vaccine

The United Kingdom has initiated clinical trials for a new Ebola vaccine, marking the first of four experimental vaccines to enter human testing following regulatory approval. Scientists at the University of Oxford developed the vaccine in just eight weeks after a public health emergency was declared in the Democratic Republic of the Congo on May 17.

The trial, led by Dr. Katrina Pollock, aims to recruit 50 healthy adults aged 18 to 55. The first doses are expected to be administered within weeks, with volunteers monitored for a year. Researchers are also collaborating with partners in Uganda to prepare for future trials in Africa. Early results on immune response and side effects may be available quickly, though full efficacy data will take longer to assess.

The current Ebola outbreak in the DRC has resulted in 625 deaths and 1,792 confirmed cases, caused by the Bundibugyo species of the virus. Unlike the Zaire strain, which has approved treatments, Bundibugyo has no specific vaccines or drugs. The outbreak remains uncontrolled in a conflict zone with highly mobile populations, increasing the urgency for an effective vaccine.

The Oxford team accelerated development by repurposing technology used in the Oxford/AstraZeneca COVID-19 vaccine. This method employs a modified chimpanzee adenovirus to deliver a fragment of the Ebola virus’s genetic code, prompting an immune response without causing infection. The vaccine has already undergone animal testing and is being manufactured by the Serum Institute of India, which has produced 620,000 doses in preparation for potential deployment.

While vaccine development typically takes a decade, researchers emphasize that no safety measures have been bypassed. Instead, parallel testing and round-the-clock collaboration have expedited the process. However, concerns linger due to rare blood clot risks associated with the COVID-19 vaccine, though experts note that Ebola’s mortality rate—around 30% for Bundibugyo—far exceeds any potential vaccine risks.

Three other experimental vaccines for Bundibugyo Ebola are also in development, including one by Moderna using mRNA technology and another by the International AIDS Vaccine Initiative, which employs a slower but proven manufacturing method.

Health officials stress that severe side effects from the vaccine are rare and that volunteers will be fully informed of potential risks. Dr. Pollock highlighted the ethical considerations of testing on healthy individuals but noted that the rapid development aligns with standard trial protocols when facing a public health crisis.

The UK’s Medicines and Healthcare Products Regulatory Agency approved the trial based on preclinical data, signaling cautious optimism in the vaccine’s potential to curb future outbreaks.